High impact by Sample, Susan
[ Table of Contents | Next Article ]
High Impact
by Susan Sample
Cardiologist's Studies Pump Research on Chronic Heart 
Failure
The number of times each research paper has been 
cited-165-reads like the systolic blood pressure of patients 
Edward M. Gilbert, M.D., treats at University of Utah Hospital. 
In fact, many of his patients participated in the clinical studies 
that earned the Utah cardiologist the distinction last summer of 
being ranked 12th in the nation for publishing "high-impact" 
papers in cardiovascular research. 
From 1993-97, Gilbert contributed to seven articles published in 
top peer-reviewed journals, which were then cited 1,157 times, 
or an average of 165.3 times per paper, during the five-year span, 
according to Science Watch, a research service group of the 
Institute for Scientific Information.
When Gilbert heard the news, "it kind of blew me away." He 
acknowledged that the articles, clinical trials of new drugs to 
treat chronic heart failure, "are pivotal findings. Usually though, 
the older the paper, the more likely it is to be cited. These were 
referred to almost as soon as they were published."
As gratifying as the accolades are, Gilbert is proudest of the 
clinical impact: "Patients now are getting these drugs prescribed 
because of these papers."
About 5 million Americans have chronic heart failure, 
sometimes referred to as congestive heart failure. Although the 
word failure might suggest a heart attack or sudden death, 
chronic heart failure is a condition resulting from an injury to the 
heart muscle, impairing the ability of the left ventricle to eject 
blood. The causes vary. Some are identifiable: coronary artery 
disease (responsible for the condition in two-thirds of the 
patients); valvular heart disorders; hypertension; thyroid disease 
or alcoholism. Other causes, referred to as idiopathic dilated 
cardiomyopathy, are unknown. The symptoms, however, are the 
same in all patients: dyspnea or shortness of breath, fatigue, fluid 
retention and an enlarged heart. 
Chronic heart failure usually is a progressive condition. The 
heart dilates and hypertrophies, becoming more spherical. This 
"pathological remodeling" causes the strength of the contraction, 
or squeezing motion, to decrease, which increases a patient's risk 
for sudden death. 
"Heart failure gets worse because of the body's nerve and 
hormone responses to the progressive enlargement. Over the 
long term, the hormones are harmful," said Gilbert. "The analogy 
I use is: if you put a Volkswagen in second gear to drive up a 
hill, it'll be okay. But if you drive it to Las Vegas, the car will 
burn out. 
"Even heart failure patients with the most stable condition have a 
50 percent chance of dying within five years." 
While the rate of heart attacks is declining in the United States, 
chronic heart failure is on the rise. "It's the most common cause 
of hospitalization in the elderly," said Gilbert. According to the 
Advisory Council to Improve Outcomes Nationwide in Heart 
Failure, the condition is "responsible for more than 11 million 
physician office visits and causes or contributes to over 3.5 
million hospitalizations in people more than 65 years old." These 
hospitalizations cost a total of $8-15 million each year, more 
than twice the cost of hospitalizations for all forms of cancer. 
"From a public health perspective, heart failure is very 
important," noted the Utah cardiologist. 
Fortunately, as reported in the high-impact papers, 
angiotensin-converting enzyme (ACE) inhibitors and 
beta-adrenergic receptor (beta) blockers not only treat the 
symptoms of chronic heart failure, but also reverse the 
progression. "Traditionally, beta-blockers were contraindicated. 
They were avoided, because it was felt the acute effects were 
harmful to the patient: lowering the heart rate and decreasing the 
squeezing function," explained Gilbert. "By starting at low 
doses, then increasing, we found patients would not only tolerate 
the drug, but over time, it had a protective factor."
As the pumping function improved, the heart returned to normal 
size and shape, reducing patients' risk of hospitalization and 
death. 
In 1975, a group of Swedish researchers introduced the concept 
of using beta-blockers to treat heart failure, although it wasn't 
until 1985 that the U of U conducted the first randomized 
clinical trial. Researchers measured the pressure in patients' 
hearts and lung veins, and used questionnaires to assess 
symptoms in an effort to measure the drugs' effect on mortality 
and morbidity. These endpoints later were assessed in 
multi-center clinical trials across the country; Utah had one of 
the largest patient enrollments.
Despite the proven ability of beta-blockers and ACE inhibitors 
to stop the progression of chronic heart failure, the drugs still 
aren't widely prescribed. "Taken together, these drugs will 
reduce the annual rate of death from heart failure by 50 percent," 
said Gilbert. "But we know that only 50 percent of the people 
who could use ACE inhibitors receive them, and just 5 percent 
receive beta-blockers. 
Many generalists don't recognize chronic heart failure in their 
patients unless they're retaining fluid."
A definitive diagnosis can be made with an echo-cardiogram, an 
ultrasound image of the heart's chambers, although physicians 
don't routinely order this test unless the patient's history suggests 
he or she is suffering from dyspnea or fatigue. Often, these 
symptoms aren't reported. "Many older people don't climb stairs 
anymore; they don't mow their lawns," said Gilbert. "They've 
moved into a one-floor condo and modified their lifestyles, so no 
one recognizes the symptoms of heart failure. Their symptoms 
are mistaken for the aging process. 
"One of the challenges is figuring out how we can identify 
patients with chronic heart failure early on," he said. Finding 
blood test markers is one possibility Gilbert would like to 
investigate. He's also looking at the bigger picture: "We need to 
help patients control diabetes, hypertension, cholesterol and 
obesity. These lead to more than half of the causes of heart 
failure in the United States." 
He acknowledged that obesity can be a "tricky" topic to discuss 
with patients, but emphasized that "it isn't a pejorative matter. 
We're not talking about it on an aesthetic level. Rather, what can 
we do to help you feel better and live longer."
The cardiologist works with a health-care team that includes a 
dietitian, nurse and exercise physiologist. "We acknowledge that 
losing weight will be hard. We don't tell patients to starve 
themselves; they'll lose muscle mass. And it's not practical to tell 
them to run a marathon. They can walk. With certainty, we can 
say that exercise will improve the symptoms of heart failure, and 
it's safe."
As Gilbert explains to his patients, "If you have an old horse and 
a full wagon load, it's hard for the horse to pull. Unload the 
wagon, and it's easier. Obesity and high blood pressure are like 
heavy loads. 
"Beta-blockers are like a whip," he adds. "If you use them 
occasionally, they help get the horse going. If you rely on the 
whip all the time, you'll kill the horse."
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